Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850465 | 1.00 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL10285822 | 1.00 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL15806843 | 0.94 | CYP1A2 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL25962289 | 0.94 | CYP1A2 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL2459458 | 0.89 | CHRNB4 (0.50) | CHRNB4CHRNA3 | |
| SCHEMBL20330340 | 0.87 | CHRNB4 (0.38) | CHRNB4CHRNA3 | |
| SCHEMBL9259241 | 0.82 | CYP1A2 (0.48) | — | |
| SCHEMBL13462239 | 0.82 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL7798503 | 0.82 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL18455133 | 0.80 | CHRNB4 (0.47) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023114733-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022261210-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-17 | — | — | US | disclosed |
| EP-1740578-B1 | 4- 2- (CYCLOALKYLAMINO) PYRIMIDIN-4-YL ] - (PHENYL) - IMIDAZOLIN-2- ONE DERIVATIVES AS P38 MAP- KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7700771-B2 | Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700771-B2 | Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | CHRNB4 25/4885CHRNA3 17/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CHRNB4 4290/4885CHRNA3 4261/4885 |
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | CHRNB4 4715/4885CHRNA3 4672/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | CHRNB4 1836/4885CHRNA3 2615/4885 |
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, ROCK2 | CHRNB4 4701/4885CHRNA3 4738/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CHRNB4 4183/4885CHRNA3 4195/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | CHRNB4 1181/4885CHRNA3 521/4885 |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | CHRNB4 1836/4885CHRNA3 2615/4885 |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MAPK1, CHUK, MAPK3 | CHRNB4 4610/4885CHRNA3 4480/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | CHRNB4 1836/4885CHRNA3 2615/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | CHRNB4 4183/4885CHRNA3 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.